Long-acting risperidone: a review of its role in the treatment of bipolar disorder

Creative Commons License

Kemp D. E., Canan F., Goldstein B. I., MCINTYRE R. S.

ADVANCES IN THERAPY, cilt.26, sa.6, ss.588-599, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 26 Sayı: 6
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1007/s12325-009-0039-0
  • Dergi Adı: ADVANCES IN THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.588-599
  • Anahtar Kelimeler: adherence, bipolar disorder, long-acting risperidone, maintenance phase, risperidone, ANXIETY TREATMENTS CANMAT, PLACEBO-CONTROLLED TRIAL, DOUBLE-BLIND, I-DISORDER, ACUTE MANIA, INJECTABLE RISPERIDONE, STEP-BD, ATYPICAL ANTIPSYCHOTICS, MAINTENANCE THERAPY, TREATMENT ADHERENCE
  • Akdeniz Üniversitesi Adresli: Hayır

Özet

Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid psychiatric and general medical conditions. Indefinite pharmacological treatment is often required, yet the modest effects of available treatments and frequent difficulties with tolerability and adherence present complex challenges to patients. Long-acting injectable medications offer a therapeutic alternative to oral mood stabilizers and may help facilitate long-term treatment adherence. This article will provide a succinct review of the latest data on the use of long-acting injectable risperidone (LAR) during the maintenance-phase treatment of bipolar disorder. The specific role of LAR in comparison to other atypical antipsychotics, and the limitations of available studies will be discussed from the perspectives of efficacy, tolerability, and sequential positioning in treatment guidelines.